Vanda Pharmaceuticals (NASDAQ:VNDA) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.09 by 33.33 percent. This is a 57.14 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $65.32 million which missed the analyst consensus estimate of $71.00 million by 8.00 percent. This is a 6.82 percent decrease over sales of $70.09 million the same period last year.
Bitcoin, Ethereum, Dogecoin Head Lower As Stocks Bleed Amid Surging Bond Yields — Analyst Says 97% Of Short-Term Holders Enter ‘Panic’ Mode
Major cryptocurrencies saw a significant decline in value on Wednesday evening following the filing of a dismissal request by Binance, Binance.US, and Changpeng Zhao in response to a Securities and Exchange Commission (SEC) lawsuit.
